Gerresheimer AG, a pharmaceutical and health care specialist in Düsseldorf, Germany, has begun producing new GX RTF Clearject syringes.
The use of high-performance plastic cop (cyclic olefin polymers) can be used for pharmaceutical products that require particularly complex packaging. The new GX RTF Clearject syringe, long 1ml, with casing, is the first type of plastic injector developed and produced by Gerresheimer.
Gerresheimer brings together the advantages of its production of glass in Pentax and the development and industrialization of new syringes in the German Technical Competence Center (TCC) at Wacker.
Tips for combining The production facilities are planned and built by the automation team of the Technical Competence center; The technical expertise of quality control and quality guidelines for primary packaging is derived from the specialist in the manufacture of glass and can be adapted to the special requirements of plastic production.
Production is based on the specific high quality requirements of pharmaceutical primary packaging materials corresponding to GMP. The new production facility covers the entire processing chain from injection molding to Finished RTF packaging.
For quality control, a series of cameras are installed at each station to check all relevant geometrical parameters and appearance defects of each product.
Cop for materials that are harmful or poisonous Drugs have stringent requirements for their own packaging. In particular, biotechnology-made active agents, can not interact with the packaging, otherwise it may have adverse effects on patients. According to the manufacturer's GX RTF syringe with a particularly weak interaction force of the packaging, the material The COP has a high ph tolerance and does not release metal ions into the drug solution , so the ph value is not shifted during storage.
The COP is particularly resistant to breakage, making it suitable for packaging hazardous or toxic substances. The syringe is manufactured by injection molding in a 8 times-fold hot runner mold. The casing is also injected together and does not need to be glued back. Therefore, the GX RTF avoids the tungsten and slag in the syringe. The precise geometry of the injection molding section reduces the dead volume in the syringe, thus reducing the residue of expensive drugs in the syringe.
The same attraction is the security of the end consumer. Syringes utilize precisely controlled high-viscosity, low-particulate silicide to provide a comprehensive syringe system with plunger rods, column rubber cork stoppling, finger flanges and closed systems to assemble the COP syringe body.